The Food and Drug Administration (FDA) announced on Friday that eight individuals in four states experienced adverse health effects after consuming Diamond Shruumz-brand microdosing chocolate bars. Microdosing, a practice gaining popularity, involves taking small, sub-perceptual doses of a drug, typically a psychedelic, with the belief that it can enhance creativity and mental well-being. This trend has particularly taken hold in Silicon Valley, with some CEOs incorporating microdosing into their daily routines.
The microdosing industry has witnessed significant growth in recent years, fueled by companies aiming to develop approved medicines from substances like MDMA. A "psychedelics renaissance" began in 2020, according to Business Insider, with psychedelics companies attracting $163.6 million in investments during the first nine months of that year. While Diamond Shruumz markets its products as microdoses, they do not contain any psychedelics. The company offers a variety of products, including chocolate bars in six flavors, all formulated with a "proprietary blend of natural ingredients," as stated in their FAQ. Their website emphasizes the absence of psilocybin, amanita, or any scheduled drugs, assuring customers of a safe and enjoyable experience.
However, the FDA reported that the individuals who consumed the chocolate bars experienced severe symptoms, including seizures, central nervous system depression, nausea, vomiting, agitation, abnormal heart rates, and fluctuations in blood pressure. All eight individuals sought medical attention, with six requiring hospitalization. Fortunately, no deaths were reported. The FDA is currently investigating the cause of these illnesses and will provide further updates as they become available. Representatives from Diamond Shruumz have not yet responded to requests for comment.
0 Comments
Name
Comment Text